Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

NCT02045836 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

865

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster
Herpes Zoster Vaccine

Interventions

BIOLOGICAL: Herpes Zoster vaccine GSK 1437173A
BIOLOGICAL: Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™

Sponsor

GlaxoSmithKline